GoodRx delays third-quarter report as revenue restatement remains incomplete

• GoodRx Holdings delayed its third-quarter 2026 Form 10-Q while completing restatements of first- and second-quarter financial statements.
• Revenue recognition errors understated Pharma Direct revenue and total revenue in both affected periods.
• The restatements also affect third-quarter financial statements; the assessment of their impact on internal controls remains incomplete.
• One or more material weaknesses in internal control over financial reporting are expected.
• The company plans to release earnings and file its Form 10-Q within the five-calendar-day extension period.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. GoodRx Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001809519-26-000192), on November 10, 2026, and is solely responsible for the information contained therein.